New monthly shot targets fatty liver in early trial
NCT ID NCT06891365
First seen Apr 18, 2026 · Last updated Apr 28, 2026 · Updated 4 times
Summary
This early-stage study tests a new medicine called NNC0581-0001 in 48 adults with fatty liver and possible liver inflammation. Participants receive either the drug or a placebo as a monthly injection for 3 months. The main goal is to check safety and how the body processes the drug. The study lasts about 58 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Parexel Research Unit
RECRUITINGHarrow, HA1 3UJ, United Kingdom
Conditions
Explore the condition pages connected to this study.